Jiao, XLiu, G YShan, C OZhao, XLi, X WGathmann, IRoyce, C2009-05-272009-05-271997-09-30Jiao X, Liu GY, Shan CO, Zhao X, Li XW, Gathmann I, Royce C. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. The Southeast Asian Journal of Tropical Medicine and Public Health. 1997 Sep; 28(3): 476-81http://imsear.searo.who.int/handle/123456789/32914The Southeast Asian Journal of Tropical Medicine and Public Health.One hundred and two Chinese out-patients with naturally acquired, previously untreated, falciparum malaria were selected to evaluate the efficacy of a new combination anti-malaria therapy, CGP 56697 (artemether plus benflumetol). In this open non-comparative trial each patient received a combination of 80 mg artemether and 480 mg benflumetol given orally at 0, 8, 24 and 48 hours (total: 320 mg artemether, 1,920 mg benflumetol). Patients were kept for 28 days in a transmission-free hospital in an area with chloroquine resistant falciparum malaria to prevent reinfection and to aid diagnosis of recrudescence. Progress and possible adverse effects were monitored by blood film parasitology, blood biochemistry assays, urinalysis, ECG and X-ray. Ninety-eight of the 102 patients were shown to be free of infection at 28 days, a 96.1% cure rate. Parasite reduction at 24 hours was 99.4%. Time to effect complete parasite clearance ranged from 24 to 54 hours (median 30 hours). Time for fever clearance ranged from 6 to 78 hours (median 18 hours). Recrudescence was low (3.9%). No significant adverse side-effects were encountered. It is concluded that CGP 56697, a combination anti-malaria therapy of artemether with benflumetol, offered a rapid and highly effective treatment for acute uncomplicated falciparum malaria in an area of chloroquine-resistant malaria in China.engAdministration, OralAdolescentAdultAntimalarials --therapeutic useArtemisininsChinaChloroquineDrug CombinationsDrug ResistanceFemaleFluorenes --therapeutic useHumansMalaria, Falciparum --drug therapyMaleMiddle AgedSesquiterpenes --therapeutic useTime FactorsTreatment OutcomeClinical Trial